London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Peff. For nearly 8 years i commuted to zurich. Had my circle of bars hotels etc i used. One week i flew out. Couldnt get a hotel. Davos or something was on. I retired to my fav bar (safari bar. Niededorf). Where i was good friends with the landlady and whinged whilst trying to find a hotel. She suggested staying with a hooker friend and linked us up. Half the price of a hotel. Central location. The girl got a 2 week sex free holiday. And did all my laundry for free. I got to live in an 80 room brothel for less than a hotel. Was an interesting 2 weeks. Just watching what went on in the streets outside. Long time ago now.
There is a an attachment below which you may find interesting which relates to Sierra's Momelotinib. It does look promising for them, which must be good for not only them of course, but us too.. 6 months before results expected to come through ie ist quarter of 2022.
Thoth2, as you know I’m a whole hearted disciple. Never met you, probably never will (unless there’s a £45per share party). I’ve put my full trust (and 500k of shares) in your hands and am following your guidance (based on your track record that I’ve observed over quite a few years now). Its my choice and I will never hold you accountable if anything (very unlikely) goes nipples vertical. However, what I’m really intrigued by is that period when you lived in a brothel!!!! Please elaborate and expand on this. C’mon SAR Have a great weekend and beyond everyone. Sorry for this ****e but had a touch of the celebratory weekend sauce I’m afraid!!??
SOG I'm glad you used the term MF. I wanted to discuss that point but my spelling is carp. In my camp I'm thinking issues with blood platelets being interfered with. Hence cytokine storms and now 3 countries reporting spike proteins moving to organs from the injection point. Appreciate we may be on a different hymn sheet here. But the whole lupus program and military games in China August 2019, then my missus close to hospitization visiting relatives December 2019 in HK..with a flu type scenario. I consider my self a critical thinker.
Thankyou SOG. Also I find it interesting have confirmed they have acquired the numbers of individuals for their Momentum programme. Also on a personal note re you getting trolled today. There are some real a holes out there who hate a reality check and when challenged they resort to personal attacks. It shows they can't communicate with a demeanor that is intelligent and able of critical thinking. Always like your posts. Sound words. When you briefly left I felt the Sareum unfolding story lost a fantastic acolyte. So glad you are back. Don't let the bar stewards get you down. Best regards Steadydanny
Certainly food for thought there Steadydanny. SRA has a fantastic pedigree. Developed alongside ICR and much to do with Michelle Garrett. An abstract from June 2017:-
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials.
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made today by Sierra Oncology, Inc. reporting on the initial progress of the two ongoing Phase 1 trials of the Chk1 inhibitor, SRA737. The full announcement can be found on Sierra Oncology's IR website*.
This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.
The SRA737 Phase 1 monotherapy trial has advanced through six single patient dose cohorts of 20, 40, 80, 160, 300 and 600 mg/day, administered under a continuous daily oral dosing regimen in 28-day cycles. Dose escalation will continue until a maximum tolerated dose (MTD) is reached, in parallel with ongoing Cohort Expansion enrolment.
Preliminary observations from the ongoing monotherapy study are as follows:
• SRA737 has been very well-tolerated to date: No Grade 2 or higher SRA737-related adverse events have been reported. No dose-limiting toxicities have been observed and an MTD has not been reached.
Note the ' no dose limiting toxicities have been observed' and maximum tolerated dose not been reached.
From 2018 :- SRA737 Combination with Immuno-Oncology
During its Program Update in February, Sierra presented preclinical data providing evidence of synergy between SRA737 and immune checkpoint blockade. Sierra is currently designing a clinical study for this combination, which potentially could be submitted to regulatory authorities in the fourth quarter of 2018.
All very impressive and lack of development has caused us to forget just how ' more commercially viable' SRA737 is.
I am thinking the stars are aligning for a deal of some sort to progress SRA737. If they do not use it they lose it along with a whole heap of costly research and investment.
Into August next week and the clock is ticking very fast. Deals are not done overnight. Plans in whatever shape of form will be in progress now ( my uptake of situation). I would estimate on commencement of development and trials, circa 100 million at least on market cap circa 3p per share increase. The market is huge and much left untouched with no competitors.
There is just so much potential in combo therapy with CHK1.
Appreciate any feedback. Please be kind. I'm no scientist but do have an understanding of DNA and RNA and cytokine storms and cytotoxicity. So in a nut shell our RNS today re a further US Patent application, of which I see on Sareums website there is a direct link to all patent applications and progress and approvals including China, Japan and parts of Europe. Makes for good reading. Then I see the Sierra TM application discussed today that effectively as I read here was a bit of jiggery pokery with their trading name fonts. So we are are awaiting 737 updates and I then look at Sierras financial position and the last thing I thought they would do is spend money they don't (yet) have on a corporate image logo update. So if you were going to a ball wouldn't you want to be seen with your best updated image? Is it a coincidence? Also enter HNWIs! It is something in my gut (re our 12 November 2020 RNS aboutSRA737 suggestion of broader applications ...) that really makes me think something is definitely being carefully and diligently rolled out. Please ignore if I am rambling without a noteable point, or politely just say I'm off the mark. Best regards Steadydanny